SPG4 frequency is 33.3% in Central Chinese HSP families with 7 novel SPAST variants identified
This observational cohort study characterized the clinical and genetic profile of hereditary spastic paraplegia type 4 (SPG4) in 63 unrelated families with hereditary spastic paraplegia (HSP) from Central China. Genetic screening was performed using whole exome sequencing to detect SPAST variants, with no comparator group reported. The primary finding was that SPAST variants accounted for 33.3% (21/63) of index patients in this cohort. Secondary outcomes included the identification of 7 novel SPAST variants and the detection of 4 previously reported exon deletions. The mean age of disease onset was 34.0 years, and 2 patients presented with complicated phenotypes, including one case of hyposmia. Safety and tolerability data were not reported. Key limitations were not explicitly stated in the provided evidence, but the study design inherently lacks randomization and a control group. The practice relevance is restrained: the finding that SPAST rearrangement is common suggests it should be considered during genetic analysis for HSP in similar populations, but this is an association only with no causation established. The clinical significance of the novel variants requires functional validation, and the observation of hyposmia as a potential phenotype is based on a single case.